Invex Therapeutics Ltd
Invex Therapeutics Ltd
Your view on IXC.AX
Overview
What the company does, where it operates, and who runs it.
About Invex Therapeutics Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Ryan Slate
- Headquarters
- 38 Rowland Street, Subiaco, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Ryan Slate
- Headquarters
- 38 Rowland Street, Subiaco, WA, AU
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders.
Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials.
The company was founded in 2019 and operates from Perth, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Invex Therapeutics Ltd. Starting points for Invex Therapeutics Ltd: EPS -AUD 0.02, beta 0.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Invex Therapeutics Ltd. Invex Therapeutics Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Invex Therapeutics Ltd. Trailing twelve-month EPS for Invex Therapeutics Ltd stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | −AUD 0.02 | −AUD 0.02 |
| Lowest estimate | −AUD 0.02 | −AUD 0.02 |
| Highest estimate | −AUD 0.02 | −AUD 0.02 |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Revenue estimates
| Total | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | AUD 0.00 | AUD 0.00 |
| Lowest estimate | AUD 0.00 | AUD 0.00 |
| Highest estimate | AUD 0.00 | AUD 0.00 |
| Number of analysts | 0 | 0 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Invex Therapeutics Ltd. Invex Therapeutics Ltd has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACR.AXAcrux Limited | Healthcare | Biotechnology | — | ||
| ADR.AXAdherium Limited | Healthcare | Medical - Devices | — | ||
| BGT.AXBio-Gene Technology Limited | Basic Materials | Agricultural Inputs | — | ||
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| CAN.AXCann Group Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| CHM.AXChimeric Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ICR.AXIntelicare Holdings Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| MEM.AXMemphasys Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PHYOFIXICO plc | Healthcare | OTC | $6.5M | ||
| PKTXProtoKinetix, Incorporated | Healthcare | OTC | $2.7M | ||
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $41.0M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $12.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $9.9M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $254.6M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $80.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $3.0M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.2M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $65.1M | ||
| POLBFPoolbeg Pharma PLC | Healthcare | OTC | $46.6M | ||
| PPBTPurple Biotech Ltd. | Healthcare | NASDAQ | $236,124 | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Invex Therapeutics Ltd.